Continue below to learn more about our full suite of STRATEGIC capabilities.
Using multiple objective decision analysis to prioritize pipeline product candidates for further investment.
Prioritizing several potential therapeutic indications for a single molecule in development.
Conducting market research with physicians and patients in the US and EU5 to develop a forecast for a pipeline asset.
Identifying molecules that would benefit from a 505(b)(2) reformulation using a proprietary drug delivery platform.
Scouting for and assessing inlicensing and M+A opportunities to build a growing product portfolio.
Developing a company valuation to support a term sheet for a Series A venture capital financing.
TNG has worked with a number of life science companies across the world to deliver strategic services. For many of our clients, we have conducted market research + analytics to test development strategies, refine target product profiles or messaging with key stakeholders, and establish realistic product-level or corporate forecasts and valuations. For others, we have assisted with product planning + strategizing, and yet for others, support in business development such as buy-side scouting + due dilligence. Here are some of our STRATEGY clients.
